1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Introduction
2.2. Define: Research Objective
2.3. Determine: Research Design
2.4. Prepare: Research Instrument
2.5. Collect: Data Source
2.6. Analyze: Data Interpretation
2.7. Formulate: Data Verification
2.8. Publish: Research Report
2.9. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges
5.2. Cumulative Impact of COVID-19

6. Gastroesophageal Reflux Disease Therapeutics Market, by Drug Type
6.1. Introduction
6.2. Antacids
6.3. H2 Receptor Blockers
6.4. Pro-kinetic Agents
6.5. Proton Pump Inhibitors (PPIs)

7. Gastroesophageal Reflux Disease Therapeutics Market, by Application
7.1. Introduction
7.2. Acid Reflux Disorders
7.3. Heartburn

8. California Gastroesophageal Reflux Disease Therapeutics Market

9. Florida Gastroesophageal Reflux Disease Therapeutics Market

10. Illinois Gastroesophageal Reflux Disease Therapeutics Market

11. New York Gastroesophageal Reflux Disease Therapeutics Market

12. Ohio Gastroesophageal Reflux Disease Therapeutics Market

13. Pennsylvania Gastroesophageal Reflux Disease Therapeutics Market

14. Texas Gastroesophageal Reflux Disease Therapeutics Market

15. Competitive Landscape
15.1. FPNV Positioning Matrix
15.1.1. Quadrants
15.1.2. Business Strategy
15.1.3. Product Satisfaction
15.2. Market Ranking Analysis
15.3. Market Share Analysis, By Key Player
15.4. Competitive Scenario
15.4.1. Merger & Acquisition
15.4.2. Agreement, Collaboration, & Partnership
15.4.3. New Product Launch & Enhancement
15.4.4. Investment & Funding
15.4.5. Award, Recognition, & Expansion

16. Company Usability Profiles
16.1. Abbott Laboratories
16.2. AstraZeneca PLC
16.3. Aurobindo Pharma Limited
16.4. Boston Scientific Corporation
16.5. Cadila Healthcare Limited
16.6. Cheplapharm Arzneimittel GmbH
16.7. Daewoong Pharmaceutical Co., Ltd
16.8. Eisai Co., Ltd.
16.9. Endogastric Solutions Inc
16.10. Endostim BV
16.11. GlaxoSmithKline PLC
16.12. Ironwood Pharmaceuticals, Inc.
16.13. Jeil Pharmaceutical Co., Ltd.
16.14. Johnson & Johnson Services, Inc.
16.15. Novartis International AG
16.16. Pfizer, Inc.
16.17. RaQualia Pharma, Inc.
16.18. Reckitt Benckiser Group PLC
16.19. SFJ Pharmaceuticals Group
16.20. SRS Pharmaceuticals Pvt. Ltd
16.21. Sun Pharmaceutical Industries Limited
16.22. Takeda Pharmaceutical Co., Ltd.
16.23. Teva Pharmaceuticals Industries Limited

17. Appendix
17.1. Discussion Guide
17.2. License & Pricing

List of Figures

FIGURE 1. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET: RESEARCH PROCESS
FIGURE 2. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET: MARKET DYNAMICS
FIGURE 3. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2020 VS 2027 (%)
FIGURE 4. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2020 VS 2027 (USD MILLION)
FIGURE 5. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2027
FIGURE 6. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ANTACIDS, 2018-2027 (USD MILLION)
FIGURE 7. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ANTACIDS, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 8. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR BLOCKERS, 2018-2027 (USD MILLION)
FIGURE 9. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR BLOCKERS, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 10. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PRO-KINETIC AGENTS, 2018-2027 (USD MILLION)
FIGURE 11. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PRO-KINETIC AGENTS, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 12. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS (PPIS), 2018-2027 (USD MILLION)
FIGURE 13. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS (PPIS), BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 14. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2020 VS 2027 (%)
FIGURE 15. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2020 VS 2027 (USD MILLION)
FIGURE 16. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2027
FIGURE 17. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ACID REFLUX DISORDERS, 2018-2027 (USD MILLION)
FIGURE 18. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ACID REFLUX DISORDERS, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 19. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY HEARTBURN, 2018-2027 (USD MILLION)
FIGURE 20. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY HEARTBURN, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 21. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET: FPNV POSITIONING MATRIX
FIGURE 22. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET: SHARE, BY KEY PLAYER, 2020
FIGURE 23. COMPETITIVE SCENARIO ANALYSIS IN UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET, BY TYPE

List of Tables

TABLE 1. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
TABLE 3. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 4. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ANTACIDS, BY STATE, 2018-2027 (USD MILLION)
TABLE 5. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR BLOCKERS, BY STATE, 2018-2027 (USD MILLION)
TABLE 6. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PRO-KINETIC AGENTS, BY STATE, 2018-2027 (USD MILLION)
TABLE 7. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS (PPIS), BY STATE, 2018-2027 (USD MILLION)
TABLE 8. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 9. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ACID REFLUX DISORDERS, BY STATE, 2018-2027 (USD MILLION)
TABLE 10. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY HEARTBURN, BY STATE, 2018-2027 (USD MILLION)
TABLE 11. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET: SCORES
TABLE 12. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET: BUSINESS STRATEGY
TABLE 13. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET: PRODUCT SATISFACTION
TABLE 14. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET: RANKING
TABLE 15. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET: SHARE, BY KEY PLAYER, 2020
TABLE 16. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET: MERGER & ACQUISITION
TABLE 17. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 18. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 19. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET: INVESTMENT & FUNDING
TABLE 20. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 21. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET: LICENSE & PRICING

Companies Mentioned

Abbott Laboratories
AstraZeneca PLC
Aurobindo Pharma Limited
Boston Scientific Corporation
Cadila Healthcare Limited
Cheplapharm Arzneimittel GmbH
Daewoong Pharmaceutical Co., Ltd
Eisai Co., Ltd.
Endogastric Solutions Inc
Endostim BV
GlaxoSmithKline PLC
Ironwood Pharmaceuticals, Inc.
Jeil Pharmaceutical Co., Ltd.
Johnson & Johnson Services, Inc.
Novartis International AG
Pfizer, Inc.
RaQualia Pharma, Inc.
Reckitt Benckiser Group PLC
SFJ Pharmaceuticals Group
SRS Pharmaceuticals Pvt. Ltd
Sun Pharmaceutical Industries Limited
Takeda Pharmaceutical Co., Ltd.
Teva Pharmaceuticals Industries Limited